JP5485172B2 - 新規な細胞増殖抑制性７−デアザプリンヌクレオシド - Google Patents

新規な細胞増殖抑制性７−デアザプリンヌクレオシド Download PDF

Info

Publication number
JP5485172B2
JP5485172B2 JP2010542509A JP2010542509A JP5485172B2 JP 5485172 B2 JP5485172 B2 JP 5485172B2 JP 2010542509 A JP2010542509 A JP 2010542509A JP 2010542509 A JP2010542509 A JP 2010542509A JP 5485172 B2 JP5485172 B2 JP 5485172B2
Authority
JP
Japan
Prior art keywords
compound
ddd
nmr
mhz
gem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010542509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509949A5 (enExample
JP2011509949A (ja
Inventor
マイケル ホセク，
ペトル ナウス，
Original Assignee
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック filed Critical インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック
Publication of JP2011509949A publication Critical patent/JP2011509949A/ja
Publication of JP2011509949A5 publication Critical patent/JP2011509949A5/ja
Application granted granted Critical
Publication of JP5485172B2 publication Critical patent/JP5485172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010542509A 2008-01-18 2009-01-15 新規な細胞増殖抑制性７−デアザプリンヌクレオシド Active JP5485172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
US61/022,247 2008-01-18
PCT/CZ2009/000004 WO2009089804A1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013266910A Division JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Publications (3)

Publication Number Publication Date
JP2011509949A JP2011509949A (ja) 2011-03-31
JP2011509949A5 JP2011509949A5 (enExample) 2013-02-21
JP5485172B2 true JP5485172B2 (ja) 2014-05-07

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542509A Active JP5485172B2 (ja) 2008-01-18 2009-01-15 新規な細胞増殖抑制性７−デアザプリンヌクレオシド
JP2013266910A Withdrawn JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013266910A Withdrawn JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP2231689B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK3133080T3 (enExample)
ES (2) ES2598503T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE041598T2 (enExample)
LT (2) LT2231689T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL2231689T3 (enExample)
PT (2) PT2231689T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MY156727A (en) * 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
KR101817221B1 (ko) * 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6650074B2 (ja) 2016-06-29 2020-02-19 ウスタフ オルガニッケ ヘミエ アー ビオヘミエ アカデミエ ヴェド ツェーエル，ヴェー．ヴェー．イー 治療に使用するための、置換チエノピロロピリミジンリボヌクレオシド
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
BR112021025443A2 (pt) * 2019-06-18 2022-02-01 Taiho Pharmaceutical Co Ltd Compostos de éster fosfato com esqueleto de pirrolopirimidina ou sal farmaceuticamente aceitável do mesmo, agentes antitumorais e composições farmacêuticas compreendendo os ditos compostos, bem como usos e usos terapêuticos dos mesmos
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
EP3133080B1 (en) 2018-08-01
NZ586610A (en) 2012-08-31
CA2711384C (en) 2016-07-26
CN101977923B (zh) 2014-10-08
HUE030767T2 (en) 2017-05-29
EP2231689B1 (en) 2016-07-20
US20090203637A1 (en) 2009-08-13
AU2009204568B2 (en) 2013-10-03
CA2711384A1 (en) 2009-07-23
EP2231689A1 (en) 2010-09-29
SI3133080T1 (sl) 2018-12-31
JP2014058567A (ja) 2014-04-03
EP3133080A1 (en) 2017-02-22
ES2598503T3 (es) 2017-01-27
US8093226B2 (en) 2012-01-10
DK2231689T3 (en) 2016-09-19
LT3133080T (lt) 2018-11-12
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
CY1118104T1 (el) 2017-06-28
TR201815961T4 (tr) 2018-11-21
CY1121364T1 (el) 2020-05-29
JP2011509949A (ja) 2011-03-31
PT2231689T (pt) 2016-10-07
HUE041598T2 (hu) 2019-05-28
CN101977923A (zh) 2011-02-16
AU2009204568A1 (en) 2009-07-23
HRP20161344T1 (hr) 2016-11-18
ES2693551T3 (es) 2018-12-12
LT2231689T (lt) 2016-10-25
PL2231689T3 (pl) 2017-01-31
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
PL3133080T3 (pl) 2018-12-31
SI2231689T1 (sl) 2016-11-30

Similar Documents

Publication Publication Date Title
EP3133080B1 (en) Novel cytostatic 7-deazapurine nucleosides
US10294262B2 (en) 7-deazapurine nucleosides for therapeutic uses
HK1234411B (en) Novel cytostatic 7-deazapurine nucleosides
HK1234411A1 (en) Novel cytostatic 7-deazapurine nucleosides
HK1149016B (en) Novel cytostatic 7-deazapurine nucleosides
US20110136754A1 (en) Novel triazole derivatives, their preparation and their application in therapeutics
HK1166325B (en) Novel 7-deazapurine nucleosides for therapeutic uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140219

R150 Certificate of patent or registration of utility model

Ref document number: 5485172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250